This is from the beginning of a post I wrote early last month on this thread.
Of course, it could be pure coincidence, but Wednesday marks exactly four years from the date that Sarepta’s PMO research collaboration agreement with Murdoch University was announced.
2 Oct 2015 A four-year agreement was announced between Sarepta Therapeutics and Murdoch University with the purpose of studying Sarepta’s's PMO (charge-neutral antisense oligonucleotide) technology for genetic diseases other than Duchenne muscular dystrophy (DMD).
The Murdoch research team, led by Prof. Steve Wilton, Perron Institute Director, and Prof. Sue Fletcher, who are both based at the Centre for Comparative Genomics, was to work in conjunction with the Perron Institute, which was to provide additional research staff members for the project.
The collaboration agreement provided the Murdoch University researchers with access to Sarepta’s PMO platform technology, as well as funding for researchers and materials while Sarepta was to have exclusive rights to license technology and/or products resulting from the research projects.
Prof. Wilton said the agreement with Sarepta allowed their Murdoch laboratory to become a pipeline of drug development and would facilitate getting the drugs from laboratory to clinical trials.
PYC Price at posting:
4.4¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)